Condition: Sickle Cell Disease · Sponsor: Theravia
The purpose of this interventional, phase II, national, multicentric, non-randomised, open-label study is to evaluate the pharmacokinetics (PK), efficacy and safety of Hydroxycarbamide Paediatric dispersible tablets with a twice daily dosing regimen in children with Sickle Celle Disease between 9 months to 11 years of age. Participants will: * Take Hydroxycarbamide twice a day every day for 12 months * Visit the clinic at screening, baseline, 1, 3, 6, 9 and 12 months
This description comes directly from the study's public registry record.
Laura Thomas-bourgneuf · + 33 1 49 70 95 83 · laura.thomas-bourgneuf@theravia.com
Nesrine Flissi · nesrine.flissi@theravia.com
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Intercommunal Créteil | Créteil, France | Recruiting |
| GHEF- Site de Marne-la-Vallée | Jossigny, France | Recruiting |
| Hôpital Bicêtre | Le Kremlin-Bicêtre, France | Recruiting |
| Institut d'Hématologie et d'oncologie pédiatrique - IHOPe | Lyon, France | Active Not Recruiting |
| Hôpital Necker-Enfants malades | Paris, France | Recruiting |
| Centre hospitalier de Cayenne | Cayenne, French Guiana | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06578507